Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -.--% | -.--% | -.--% |
2015 | GeneLink Inc. Emerged from Bankruptcy | CI |
2015 | Second Amended Reorganization Plan and Disclosure Statement Approved for GeneLink Inc. | CI |
Business Summary
Sales per Business
USD in Million | 2011 | Weight | 2012 | Weight | Delta |
---|---|---|---|---|---|
GeneLink
75.7
%
| 0 | 0.5 % | 2 | 75.7 % | +7,021.96% |
GeneWize
24.3
%
| 5 | 99.5 % | 1 | 24.3 % | -88.84% |
Sales per region
USD in Million | 2011 | Weight | 2012 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 5 | 100.0 % | 2 | 100.0 % | -54.40% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Robert Ricciardi
FOU | Founder | 77 | 21/94/21 |
Bernard Kasten
CEO | Chief Executive Officer | 77 | 01/99/01 |
Michael Smith
DFI | Director of Finance/CFO | 56 | 01/12/01 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Bernard Kasten
CEO | Chief Executive Officer | 77 | 01/99/01 |
Robert Ricciardi
FOU | Founder | 77 | 21/94/21 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 269,377,848 | 265,018,689 ( 98.38 %) | 4,359,159 ( 1.618 %) | 98.38 % |
Company contact information
Sector
Sales per Business
1st Jan change | Capi. | |
---|---|---|
-.--% | 265 | |
-17.86% | 8.35B | |
+39.98% | 3.58B | |
-8.06% | 2.47B | |
-38.71% | 2.46B | |
-7.96% | 2.36B | |
-12.67% | 1.78B | |
-19.73% | 1.53B | |
-40.78% | 1.21B | |
+8.32% | 1.12B |
- Stock Market
- Equities
- GNLKQ Stock
- Company GeneLink, Inc.